Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

via Two years ago, when investigators for Daiichi Sankyo gave its experimental Duchenne muscular dystrophy drug to the very first patient in a clinical trial, the company confidently hailed the move as a big step toward a marketing approval and launch in 2020. But DMD drug development isn’t that simple.

article source